Massmutual Trust Co. FSB ADV Boosts Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Massmutual Trust Co. FSB ADV grew its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 15.1% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 4,680 shares of the biopharmaceutical company’s stock after buying an additional 615 shares during the period. Massmutual Trust Co. FSB ADV’s holdings in Regeneron Pharmaceuticals were worth $4,919,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also modified their holdings of the company. West Paces Advisors Inc. raised its stake in Regeneron Pharmaceuticals by 575.0% during the 1st quarter. West Paces Advisors Inc. now owns 27 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 23 shares during the last quarter. Crewe Advisors LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the first quarter worth about $28,000. MCF Advisors LLC increased its holdings in Regeneron Pharmaceuticals by 50.0% in the fourth quarter. MCF Advisors LLC now owns 36 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 12 shares during the last quarter. Criterion Capital Advisors LLC acquired a new position in Regeneron Pharmaceuticals in the fourth quarter valued at approximately $37,000. Finally, BOK Financial Private Wealth Inc. acquired a new position in shares of Regeneron Pharmaceuticals during the first quarter worth approximately $37,000. 83.31% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

REGN has been the subject of a number of recent analyst reports. StockNews.com lowered Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, April 30th. Wells Fargo & Company upped their price objective on shares of Regeneron Pharmaceuticals from $1,125.00 to $1,200.00 and gave the stock an “overweight” rating in a report on Friday. Truist Financial reaffirmed a “buy” rating and issued a $1,200.00 price target (up from $1,135.00) on shares of Regeneron Pharmaceuticals in a research report on Friday. Cantor Fitzgerald boosted their price target on Regeneron Pharmaceuticals from $925.00 to $1,000.00 and gave the company a “neutral” rating in a research note on Monday, July 22nd. Finally, Canaccord Genuity Group reiterated a “buy” rating and set a $1,152.00 target price on shares of Regeneron Pharmaceuticals in a research report on Thursday, June 27th. One analyst has rated the stock with a sell rating, four have issued a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $1,097.05.

Insider Buying and Selling

In related news, Director Michael S. Brown sold 1,172 shares of the business’s stock in a transaction that occurred on Tuesday, May 28th. The stock was sold at an average price of $974.86, for a total transaction of $1,142,535.92. Following the completion of the sale, the director now directly owns 1,382 shares in the company, valued at $1,347,256.52. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, Director Michael S. Brown sold 1,172 shares of the stock in a transaction on Tuesday, May 28th. The stock was sold at an average price of $974.86, for a total value of $1,142,535.92. Following the sale, the director now directly owns 1,382 shares in the company, valued at $1,347,256.52. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Joseph J. Larosa sold 1,866 shares of the stock in a transaction dated Thursday, July 11th. The shares were sold at an average price of $1,088.95, for a total value of $2,031,980.70. Following the completion of the transaction, the executive vice president now owns 37,937 shares in the company, valued at approximately $41,311,496.15. The disclosure for this sale can be found here. Insiders sold 65,074 shares of company stock worth $64,546,123 in the last 90 days. Insiders own 7.48% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN traded down $10.91 during mid-day trading on Monday, hitting $1,071.28. 619,442 shares of the company traded hands, compared to its average volume of 471,509. The stock has a 50-day moving average price of $1,043.43 and a two-hundred day moving average price of $983.16. The stock has a market cap of $118.04 billion, a price-to-earnings ratio of 31.77, a P/E/G ratio of 2.34 and a beta of 0.13. Regeneron Pharmaceuticals, Inc. has a 1 year low of $765.28 and a 1 year high of $1,115.00. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.51 and a current ratio of 5.96.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 EPS for the quarter, topping analysts’ consensus estimates of $8.93 by $2.63. The firm had revenue of $3.55 billion during the quarter, compared to analysts’ expectations of $3.38 billion. Regeneron Pharmaceuticals had a net margin of 32.04% and a return on equity of 16.80%. The firm’s revenue for the quarter was up 12.3% compared to the same quarter last year. During the same period in the previous year, the company earned $8.79 EPS. Equities analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 37.38 earnings per share for the current year.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.